Search results for "fen"

showing 10 items of 3710 documents

Psychoanalytically-Oriented Inpatient Psychotherapy of Somatoform Disorders

2008

Somatoform disorders have been neglected in psychoanalytic publications. Unlike the descriptive approach of DSM-IV and ICD-10, sophisticated psychoanalytical models have been proposed for many years explaining the development of physical symptoms without definable medical cause. Based on a review of the psychoanalytic models of somatization and conversion, this article explores difficulties in the medical and psychotherapeutic treatments of somatoform disorders. The unique tradition of psychosomatic inpatient treatment in Germany is illustrated by the psychoanalytic treatment setting at the University of Mainz. A case report of a somatoform patient shows how childhood trauma is activated an…

medicine.medical_specialtyPsychotherapistmedicine.medical_treatmentArt therapyModels PsychologicalGroup psychotherapyGermanymedicineHumansPsychoanalytic theorySomatoform DisordersPsychiatryAgedDefense MechanismsDance TherapySocial environmentMultimodal therapyGeneral Medicinemedicine.diseasePsychoanalytic TherapyHospitalizationPsychiatry and Mental healthClinical PsychologyMentalizationChronic DiseaseWorking throughFemalePsychologySomatizationThe Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry
researchProduct

New strategies for medical management of overactive bladder in children.

2011

Purpose of review The medical treatment of children with non-neurogenic overactive bladder syndrome (OAB) is still limited to a small number of drugs approved for use in childhood according to the national regulations of each country. Recent findings Over the last few years, there were several studies on the use of antimuscarinics other than oxybutynin in children, as well as some on the use of extended release oxybutynin and tolterodine and transdermal oxybutynin. It was shown that the combination of two different anticholinergics might be a well tolerated and successful option in children with OAB refractory to monotherapy, as well as administration of a receptor-selective antimuscarinic …

medicine.medical_specialtyQuinuclidinesBotulinum ToxinsCombination therapyTolterodine TartrateNortropanesUrologyPhenylpropanolamineUrologyUrinationMuscarinic AntagonistsBenzilatesCresolsTetrahydroisoquinolinesmedicineHumansBenzhydryl CompoundsOxybutyninIntensive care medicineChildSolifenacinbusiness.industryUrinary Bladder OveractiveStandard treatmentSolifenacin Succinatemedicine.diseaseBotulinum toxinReceptors MuscarinicOveractive bladderMandelic AcidsPropiverineTolterodinebusinessmedicine.drugCurrent opinion in urology
researchProduct

Response to dopamine agonists of the rat isolated uterus.

1993

1. Quinpirole did not produce any effect in isolated uterus from oestrogenized rats even when it is contracted by KCl (37 mM). 2. Fenoldopam produced a relaxant effect on rat isolated uterus contracted by KCl which was not significantly modified by SCH 23390. 3. Reserpine decreased the effect of the lowest doses of fenoldopam. In reserpinized rats, propranolol (10(-9), 10(-8), 10(-7) M) antagonized the effect of the lowest doses of fenoldopam and neither SCH 23390, sulpiride nor ranitidine modified the effect of fenoldopam. 4. The results confirm our previous finding that DA1-receptors are not functional in our preparation. The effect of fenoldopam was partially due to a catecholamine-relea…

medicine.medical_specialtySerotoninQuinpiroleReserpineFenoldopamDopamine AgentsUterusPropranololPharmacologyFenoldopamIn Vitro TechniquesDopamine agonistchemistry.chemical_compoundUterine ContractionQuinpiroleCatecholaminesInternal medicineReceptors Adrenergic betamedicineAnimalsErgolinesRats WistarPharmacologySCH-23390ChemistryReserpineAcetylcholineRatsEndocrinologymedicine.anatomical_structureFemale2345-Tetrahydro-78-dihydroxy-1-phenyl-1H-3-benzazepineSulpiridemedicine.drugGeneral pharmacology
researchProduct

Treatment strategies for cancer patients with breakthrough pain.

2009

Breakthrough pain (BTP) is a transitory flare of pain superimposed on an otherwise stable pain pattern in patients treated with opioids. It is normally severe in intensity, has a rapid onset, has a variable duration (on average 30 min) and is considered a negative prognostic factor. OBJECTIVE: To verify the data in the literature about therapy strategies for BTP in cancer patients. METHODS: To find clinical trials investigating drug therapy for BTP. CONCLUSION: The treatment of BTP in cancer patients receiving opioids is principally based on the use of opioids, preferentially with a short onset. Fentanyl delivered by recently developed systems seems to be the best option to cover the tempor…

medicine.medical_specialtySettore MED/06 - Oncologia MedicaBreakthrough PainPainFentanylPharmacotherapyNeoplasmsInternal medicinemedicineAnimalsHumansPharmacology (medical)In patientPain MeasurementPharmacologybusiness.industryCancerGeneral Medicinemedicine.diseaseAnalgesics OpioidFentanylClinical trialTreatment OutcomeAnesthesiaTreatment strategycancer pain opiods breakthrough painbusinessCancer painmedicine.drug
researchProduct

Determinants of adherence to osteoporosis treatment in clinical practice.

2006

Introduction: Poor adherence to prescribed treatments is widespread in clinical practice and this can lead to potentially life-threatening events. This problem is apparently very common for osteoporosis treatment but the causes of discontinuation and low compliance are complex and poorly defined. Methods: Global adherence to osteoporosis treatment was specifically addressed in a nation-wide survey carried out in 9851 postmenopausal women referred to 141 Italian centres for osteoporosis management for a follow-up assessment, at least one year after having been prescribed a treatment with one of the following drugs: calcium±vitamin D supplements alone (CaVitD), hormone replacement therapy (HR…

medicine.medical_specialtySettore MED/09 - Medicina InternaHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisosteoporosis; Determinants; Treatment adherence; Treatmentadherence; compliance; osteoporosis; persistence; treatmentInternal medicinemedicineTreatment adherenceHumansRaloxifeneDosingVitamin DDeterminantsOsteoporosis PostmenopausalAgedAdherence Compliance Osteoporosis Persistence TreatmentBone Density Conservation Agentsbusiness.industryHormone replacement therapy (menopause)Middle Agedmedicine.diseaseosteoporosisRheumatologyDiscontinuationMenopauseTreatmentItalyOrthopedic surgeryPhysical therapyPatient ComplianceCalciumFemalebusinessmedicine.drugOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
researchProduct

The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates

2007

Beyond total low-density-lipoproteins (LDL) levels, increasing evidence suggests that the 'quality' of LDL exerts a great influence on the cardiovascular risk. Several studies have also shown that the therapeutic modulation of LDL size is of benefit in reducing the risk of cardiovascular events. Hypolipidaemic treatment is able to alter LDL subclass distribution but strong variations have been noticed among different agents. Fibrates have a major impact on triglyceride metabolism and in modulating LDL size and subclasses, but variations exist among the different molecules.A literature search (by Medline and Scopus) was performed using the following headings: 'small dense LDL', 'LDL size', '…

medicine.medical_specialtySmall dense ldlClofibric AcidFenofibrateInternal medicinemedicineLow densityHumansGemfibrozilClinical significanceParticle SizeDyslipidemiasHypolipidemic AgentsBezafibrateFenofibratebusiness.industryBezafibrateDense low density lipoproteinFenofibrate Gemfibrozil Subfractions TherapyLdl subfractionsFibric AcidsGeneral MedicineLipoproteins LDLTreatment OutcomeEndocrinologylipids (amino acids peptides and proteins)CiprofibrateBezafibrateGemfibrozilbusinessmedicine.drug
researchProduct

Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?

2015

Simvastatin and fenofibrate are the most frequently co-prescribed drugs for the treatment of dyslipidemia, manifesting beneficial effects on non-lipid parameters as well. The combination of these two drugs has been shown to increase success in the management of combined hyperlipidemia. Their different mechanism of action allows for the targeting of two types of lipid abnormalities: increased cholesterol and atherogenic dyslipidemia. Clinical studies have demonstrated that statin and fibrate combination therapy is effective in improving multiple lipid abnormalities, that may further decrease overall cardiovascular (CV) risk of patients with combined dyslipidemia. However, the clinical use of…

medicine.medical_specialtyStatinFenofibrateCombination therapymedicine.drug_classbusiness.industrynutritional and metabolic diseasesFibratemedicine.diseaseClinical trialCombined hyperlipidemiaSimvastatinInternal medicinemedicinelipids (amino acids peptides and proteins)businessDyslipidemiamedicine.drug
researchProduct

ESRA19-0278 Sufentanil sublingual tablet system (SSTS) in post-operative pain: a case series

2019

Background and aims SSTS is a preprogrammed, non invasive, patient-activated bed-side system that enables patients to manage moderate-severe acute pain in a hospital setting. Our aim is to evaluate efficacy, ease of use of SSTS, patients and nurses’ satisfaction. Methods We evaluate pain control and general satisfaction in patients treated with SSTS after general or orthopedic prosthetic surgery. Enrollment started on April the 1st at Policlinico Paolo Giaccone in Palermo and is still ongoing. SSTS allows patients to self-administer a 15-μg sufentanil tablet sublingually with a 20-minute lockout, up to 72 hours. We visit patients three times per day, recording pain control (NRS scale), arte…

medicine.medical_specialtySublingual Tabletbusiness.industryNauseaAnalgesicKetorolacSufentanilBlood pressureAnesthesiaOrthopedic surgeryVomitingMedicinemedicine.symptombusinessmedicine.drugE-Poster Viewing Abstracts
researchProduct

Cognitive effects of labeled addictolytic medications

2017

Abstract Introduction Alcohol, tobacco, and illegal drug usage is pervasive throughout the world, and abuse of these substances is a major contributor to the global disease burden. Many pharmacotherapies have been developed over the last 50 years to target addictive disorders. While the efficacy of these pharmacotherapies is largely recognized, their cognitive impact is less known. However, all substance abuse disorders are known to promote cognitive disorders like executive dysfunction and memory impairment. These impairments are critical for the maintenance of addictive behaviors and impede cognitive behavioral therapies that are regularly administered in association with pharmacotherapie…

medicine.medical_specialtySubstance-Related Disordersmedia_common.quotation_subjectAlcohol abuse03 medical and health scienceschemistry.chemical_compoundCognition0302 clinical medicinemedicineAnimalsHumansVareniclinePsychiatryBiological PsychiatryNalmefenemedia_commonPharmacologyAddictionCognitionmedicine.disease030227 psychiatrySubstance abusechemistryPsychology030217 neurology & neurosurgeryCentral Nervous System AgentsClinical psychologymedicine.drugExecutive dysfunctionBuprenorphineProgress in Neuro-Psychopharmacology and Biological Psychiatry
researchProduct

Menopause symptom management in women with dyslipidemias: An EMAS clinical guide.

2020

Abstract Introduction Dyslipidemias are common and increase the risk of cardiovascular disease. The menopause transition is associated with an atherogenic lipid profile, with an increase in the concentrations of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), apolipoprotein B (apoB) and potentially lipoprotein (a) [Lp(a)], and a decrease in the concentration of high-density lipoprotein cholesterol (HDL-C). Aim The aim of this clinical guide is to provide an evidence-based approach to management of menopausal symptoms and dyslipidemia in postmenopausal women. The guide evaluates the effects on the lipid profile both of menopausal hormone therapy an…

medicine.medical_specialtyTiboloneDydrogesteroneGeneral Biochemistry Genetics and Molecular BiologyVaginal estrogen03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOspemifeneInternal medicinemedicineHumansMass Screening030212 general & internal medicineDyslipidemias030219 obstetrics & reproductive medicinemedicine.diagnostic_testbusiness.industryHypertriglyceridemiaObstetrics and Gynecologymedicine.diseaseLipidsMenopauseEndocrinologychemistrylipids (amino acids peptides and proteins)FemaleMenopauseLipid profilebusinessDyslipidemiamedicine.drugMaturitas
researchProduct